Evolving Resistance Among Gram-positive Pathogens

August 30, 2015 at 3:29 pm

Clinical Infectious Diseases SEP 15, 2015 V.61 Suppl.2 S48-S57

Jose M. Munita, Arnold S. Bayer, and Cesar A. Arias

1Division of Infectious Diseases, Department of Internal Medicine

2Department of Microbiology and Molecular Genetics, University of Texas Medical School at Houston

3Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

4David Geffen School of Medicine at UCLA, Los Angeles, California

5International Center for Microbial Genomics

6Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia

7Clinica Alemana de Santiago, Universidad del Desarrollo, Chile

Correspondence: Cesar A. Arias, MD, PhD, University of Texas Medical School at Houston, 6431 Fannin St, MSB 2.112, Houston, TX 77030 (cesar.arias@uth.tmc.edu).

Antimicrobial therapy is a key component of modern medical practice and a cornerstone for the development of complex clinical interventions in critically ill patients.

Unfortunately, the increasing problem of antimicrobial resistance is now recognized as a major public health threat jeopardizing the care of thousands of patients worldwide.

Gram-positive pathogens exhibit an immense genetic repertoire to adapt and develop resistance to virtually all antimicrobials clinically available. As more molecules become available to treat resistant gram-positive infections, resistance emerges as an evolutionary response.

Thus, antimicrobial resistance has to be envisaged as an evolving phenomenon that demands constant surveillance and continuous efforts to identify emerging mechanisms of resistance to optimize the use of antibiotics and create strategies to circumvent this problem.

Here, we will provide a broad perspective on the clinical aspects of antibiotic resistance in relevant gram-positive pathogens with emphasis on the mechanistic strategies used by these organisms to avoid being killed by commonly used antimicrobial agents.




Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Epidemiología, Metodos diagnosticos, Resistencia bacteriana, Sepsis.

Telavancin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections Editor’s Choice: Inflammation in Chronic HIV Infection: What Can We Do?


August 2015
« Jul   Sep »

Most Recent Posts

%d bloggers like this: